U.S. markets closed
  • S&P 500

    4,662.85
    +3.82 (+0.08%)
     
  • Dow 30

    35,911.81
    -201.79 (-0.56%)
     
  • Nasdaq

    14,893.75
    +86.95 (+0.59%)
     
  • Russell 2000

    2,162.46
    +3.02 (+0.14%)
     
  • Crude Oil

    84.45
    +0.63 (+0.75%)
     
  • Gold

    1,815.00
    -1.50 (-0.08%)
     
  • Silver

    22.93
    +0.02 (+0.07%)
     
  • EUR/USD

    1.1408
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    1.7720
    +0.0610 (+3.57%)
     
  • GBP/USD

    1.3668
    -0.0011 (-0.08%)
     
  • USD/JPY

    114.3760
    +0.1760 (+0.15%)
     
  • BTC-USD

    43,065.96
    -31.93 (-0.07%)
     
  • CMC Crypto 200

    1,037.76
    +12.03 (+1.17%)
     
  • FTSE 100

    7,542.95
    -20.90 (-0.28%)
     
  • Nikkei 225

    28,341.63
    +217.35 (+0.77%)
     

Insider Buying: The Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Co-Founder Just Bought 1.5% More Shares

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) shareholders (or potential shareholders) will be happy to see that the Co-Founder, Sujal Patel, recently bought a whopping US$1.2m worth of stock, at a price of US$4.72. While that only increased their holding size by 1.5%, it is still a big swing by our standards.

See our latest analysis for Nautilus Biotechnology

The Last 12 Months Of Insider Transactions At Nautilus Biotechnology

In fact, the recent purchase by Sujal Patel was the biggest purchase of Nautilus Biotechnology shares made by an insider individual in the last twelve months, according to our records. That implies that an insider found the current price of US$5.06 per share to be enticing. Of course they may have changed their mind. But this suggests they are optimistic. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. In this case we're pleased to report that the insider purchases were made at close to current prices.

In the last twelve months Nautilus Biotechnology insiders were buying shares, but not selling. They paid about US$5.32 on average. I'd consider this a positive as it suggests insiders see value at around the current price. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
insider-trading-volume

Nautilus Biotechnology is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It's great to see that Nautilus Biotechnology insiders own 32% of the company, worth about US$202m. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

What Might The Insider Transactions At Nautilus Biotechnology Tell Us?

The recent insider purchases are heartening. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Nautilus Biotechnology. Nice! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Nautilus Biotechnology. Be aware that Nautilus Biotechnology is showing 4 warning signs in our investment analysis, and 2 of those are a bit unpleasant...

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.